BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...3/26/19 $288.9 $2,345.2 $2,310.0 -2% Cellular Biomedicine Group Inc. (NASDAQ:CBMG) 3/22/19 $17.5 $324.9 $317.8 -2% Oragenics Inc....
BioCentury | Jul 11, 2016
Financial News

Oragenics completes private placement

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla. Business: Dental, Infectious, Diagnostic Date completed: 2016-06-30 Type: Private placement Raised: $4.7 million Shares: 9 million Price: $0.52 Shares after offering: 49.1 million Investors: Koski Family L.P.; Intrexon Corp. ;...
BioCentury | Aug 24, 2015
Clinical News

Intrexon, Oragenics preclinical data

...In rodents infected with C. difficile, Oragenics’ lead clinical candidate from its set of MU1140 analogs...
...The analogs are lantibiotic peptides targeting the bacterial cell wall component lipid II. Next quarter, Oragenics...
...to develop and commercialize lantibiotics (see BioCentury, June 11, 2012). Intrexon Corp. (NYSE:XON), Germantown, Md. Oragenics Inc....
BioCentury | Aug 3, 2015
Company News

Intrexon, Oragenics deal

...Intrexon granted Oragenics exclusive, worldwide rights to develop and commercialize biotherapeutics based on the ActoBiotics genetically...
...declined to disclose details, and Oragenics could not be reached. Intrexon Corp. (NYSE:XON), Germantown, Md. Oragenics Inc....
...could not be reached. Intrexon Corp. (NYSE:XON), Germantown, Md. Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla. Intrexon granted Oragenics...
BioCentury | Nov 10, 2014
Company News

Oragenics management update

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla. Business: Dental, Infectious, Diagnostic Resigned: John Bonfiglio as president, CEO and a director; CFO Michael Sullivan becomes interim principal executive officer WIR Staff Dental Diagnostic Infectious...
BioCentury | Apr 28, 2014
Company News

Oragenics management update

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla. Business: Dental, Infectious, Diagnostic Hired: Al Fosmoe as SVP of operations/product development WIR Staff Dental Diagnostic Infectious...
BioCentury | Nov 25, 2013
Financial News

Oragenics completes follow-on

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla. Business: Dental, Infectious, Diagnostic Date completed: 11/15/13 Type: Follow-on Raised: $11 million Shares: 4.4 million Price: $2.50 Shares after offering: 34.9 million Underwriter: Griffin Securities WIR Staff Dental Diagnostic Infectious...
BioCentury | Oct 14, 2013
Company News

Intrexon, Oragenics deal

...Intrexon will be responsible for technology discovery, cell-engineering development, and parts of the manufacturing process. Oragenics...
...the deal. Intrexon received a technology access fee of $6 million, payable in 1.3 million Oragenics...
...for undisclosed development milestones, plus royalties. Griffin Securities advised Oragenics. Intrexon Corp. (NYSE:XON), Germantown, Md. Oragenics Inc....
BioCentury | Aug 19, 2013
Financial News

Oragenics financial update

...of its securities. The company, which closed Friday at $3.09, has 27.5 million shares outstanding. Oragenics Inc....
BioCentury | Apr 15, 2013
Clinical News

Hemispherx regulatory update

U.S. Patent No. 5,550,111 issued to Temple University covering dual action oligoadenylate antiviral derivatives that have the potential to treat chronic fatigue syndrome, hepatitis B and HIV infections. HEMX has exclusive rights to the patent....
Items per page:
1 - 10 of 105
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...3/26/19 $288.9 $2,345.2 $2,310.0 -2% Cellular Biomedicine Group Inc. (NASDAQ:CBMG) 3/22/19 $17.5 $324.9 $317.8 -2% Oragenics Inc....
BioCentury | Jul 11, 2016
Financial News

Oragenics completes private placement

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla. Business: Dental, Infectious, Diagnostic Date completed: 2016-06-30 Type: Private placement Raised: $4.7 million Shares: 9 million Price: $0.52 Shares after offering: 49.1 million Investors: Koski Family L.P.; Intrexon Corp. ;...
BioCentury | Aug 24, 2015
Clinical News

Intrexon, Oragenics preclinical data

...In rodents infected with C. difficile, Oragenics’ lead clinical candidate from its set of MU1140 analogs...
...The analogs are lantibiotic peptides targeting the bacterial cell wall component lipid II. Next quarter, Oragenics...
...to develop and commercialize lantibiotics (see BioCentury, June 11, 2012). Intrexon Corp. (NYSE:XON), Germantown, Md. Oragenics Inc....
BioCentury | Aug 3, 2015
Company News

Intrexon, Oragenics deal

...Intrexon granted Oragenics exclusive, worldwide rights to develop and commercialize biotherapeutics based on the ActoBiotics genetically...
...declined to disclose details, and Oragenics could not be reached. Intrexon Corp. (NYSE:XON), Germantown, Md. Oragenics Inc....
...could not be reached. Intrexon Corp. (NYSE:XON), Germantown, Md. Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla. Intrexon granted Oragenics...
BioCentury | Nov 10, 2014
Company News

Oragenics management update

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla. Business: Dental, Infectious, Diagnostic Resigned: John Bonfiglio as president, CEO and a director; CFO Michael Sullivan becomes interim principal executive officer WIR Staff Dental Diagnostic Infectious...
BioCentury | Apr 28, 2014
Company News

Oragenics management update

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla. Business: Dental, Infectious, Diagnostic Hired: Al Fosmoe as SVP of operations/product development WIR Staff Dental Diagnostic Infectious...
BioCentury | Nov 25, 2013
Financial News

Oragenics completes follow-on

Oragenics Inc. (NYSE-M:OGEN), Alachua, Fla. Business: Dental, Infectious, Diagnostic Date completed: 11/15/13 Type: Follow-on Raised: $11 million Shares: 4.4 million Price: $2.50 Shares after offering: 34.9 million Underwriter: Griffin Securities WIR Staff Dental Diagnostic Infectious...
BioCentury | Oct 14, 2013
Company News

Intrexon, Oragenics deal

...Intrexon will be responsible for technology discovery, cell-engineering development, and parts of the manufacturing process. Oragenics...
...the deal. Intrexon received a technology access fee of $6 million, payable in 1.3 million Oragenics...
...for undisclosed development milestones, plus royalties. Griffin Securities advised Oragenics. Intrexon Corp. (NYSE:XON), Germantown, Md. Oragenics Inc....
BioCentury | Aug 19, 2013
Financial News

Oragenics financial update

...of its securities. The company, which closed Friday at $3.09, has 27.5 million shares outstanding. Oragenics Inc....
BioCentury | Apr 15, 2013
Clinical News

Hemispherx regulatory update

U.S. Patent No. 5,550,111 issued to Temple University covering dual action oligoadenylate antiviral derivatives that have the potential to treat chronic fatigue syndrome, hepatitis B and HIV infections. HEMX has exclusive rights to the patent....
Items per page:
1 - 10 of 105